NCT05646992 Uterus Transplantation to Treat Infertility
| NCT ID | NCT05646992 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Johns Hopkins University |
| Condition | Uterine Factor Infertility |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2033-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 40 participants in total. It began in 2023-03-01 with a primary completion date of 2033-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research study will use uterus transplantation to treat uterine factor infertility, also known as the inability to bear children due to not having a uterus. The purpose of this study is to enable women seeking genetically-related children and the childbearing experience to experience pregnancy and birth a child. In this study, living donors will undergo surgery to give the donor's uterus to another woman. The woman who receives the transplant will take immunosuppression to keep the uterus and herself healthy. Because taking immunosuppressive medicine has side effects, uterus transplantation is intended to be temporary, lasting about 5 years. The goals of the study are successful pregnancy and the birth of one, and possibly two, healthy babies per transplant patient. The uterus is to be removed and immunosuppression stopped following the birth of a child. Offspring are delivered by Caesarian section, at which time the transplant may also be removed. Transplant candidates must have fertilized, frozen (cryopreserved) embryos at a Johns Hopkins facility before undergoing transplantation. Transplant candidates will be asked to identify candidates' potential uterus donor. Altruistic donors, or women who want to donate without knowing a potential recipient, may also participate. All potential donors will be screened to see if the donors are a good match for a recipient and are healthy enough to have the donation surgery. Study Duration: * Uterus Donors: Screening through about 12 months following the transplant operation. * Uterus Recipients: Recipients may have the uterus for about 5 years. After the transplant is removed, the study team will ask for yearly follow-ups for another 5 years. * Children born from transplanted uteruses: The study team asks to follow offspring yearly through age 21 years.
Eligibility Criteria
INCLUSION CRITERIA - Recipient Inclusion Criteria: * Genotypic female of any race, color, or ethnicity. * Uterine factor infertility. * Aged 18-38 years at time of egg retrieval. * Strong desire to undergo uterus transplant in order to become pregnant and give birth to a child. * Embryo cryopreservation with embryos located at Johns Hopkins: * Has a minimum of 4-8 cryopreserved normal embryos following Preimplantation Genetic Screening (PGS-screening). OR o Is willing to undergo egg retrieval, in vitro fertilization, and PGS-screening to cryopreserve a minimum of 4-8 normal embryos. * Willingness to undergo embryo implantation after uterus transplantation to achieve pregnancy. * In the opinion of the study team, makes a reasonable effort to identify and refer her own potential uterus donor to the study team. * Completes the protocol informed consent form. * Non-smoker, defined by having never smoked or having quit \>6 consecutive months prior to screening. * No co-existing medical condition which, in the opinion of the study team, could affect the immunosuppression protocol, surgical procedure, or ability to be pregnant or bear a child. (See Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of uterus transplantation.) * Negative serum pregnancy test. * Blood type compatible with donor. * Negative crossmatch with donor. * Patient agrees to comply with the protocol and states a dedication to the treatment regime. * Agrees to uterus explanation following birth of a child and or 5 years without successful pregnancy. Donor Inclusion Criteria: * Genotypic female with an intact uterus. * Medical history includes known successful pregnancy (e.g., gravid uterus). * Aged 25 - 65 years. * Consents to uterus donation and required pre-donation screening. * For females of child-bearing potential: Negative serum pregnancy test. * Blood type compatible with recipient. * Negative crossmatch with recipient. Donor and Recipient Inclusion Criteria: * USA citizen or equivalent. * No co-existing psycho-social problems (i.e., alcoholism, drug abuse). * BMI ≤35 o A higher BMI may be accepted at the discretion of the study team. * Negative for HIV at transplant. * Negative for malignancy for past 5 years. EXCLUSION CRITERIA- Donor and Recipient Exclusion Criteria: * Positive for any of the following conditions: * Insulin-dependent diabetes mellitus. * Untreated sepsis. * HIV (active or seropositive). * Active tuberculosis. * Active Hepatitis B infection. * Active Hepatitis C infection. * Viral encephalitis. * Toxoplasmosis. * Current/recent (within 3 months of donation/screening consent) IV drug abuse. * Significant cardiac disease * Significant vascular disease o * Sensitized recipients with high levels (50%) of panel-reactive Human Leukocyte Antigens (HLA) antibodies. * Conditions that may impact the success of the surgical procedure or increase the risk of postoperative complications including inherited coagulopathies like Hemophilia, Von-Willebrand's disease, Protein C and S deficiency, Thrombocythemias, Thalassemias, Sickle Cell disease, etc. * Mixed connective tissue diseases and collagen diseases that can result in poor wound healing after surgery. * Severe neurologic deficits. * Patients considered unsuitable per the consulted Psychiatric/Psychologic appraisal. * A history of medical non-compliance. Donor Only Exclusion Criteria: * Previous injury to the uterus including giving birth by Cesarean section. * History of radiation therapy to the abdominal area. * Other medical conditions, as determined by the study physicians, that would preclude donation. Recipient Only Exclusion Criteria: • Conditions that, in the opinion of the study team, may expose the recipient to unacceptable risks under immunosuppressive treatment.
Contact & Investigator
Richard J Redett, MD
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT05646992 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 38 Years, studying Uterine Factor Infertility. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05646992 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05646992 currently recruiting?
Yes, NCT05646992 is actively recruiting participants. Contact the research team at jlittl38@jhmi.edu for enrollment information.
Where is the NCT05646992 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT05646992 clinical trial?
NCT05646992 is sponsored by Johns Hopkins University. The principal investigator is Richard J Redett, MD at Johns Hopkins University. The trial plans to enroll 40 participants.